Incidence and risk factors of exacerbations among COPD patients in primary health care: APMPOC study.

BMC Public Health
Eulàlia BorrellGlòria Tintoré

Abstract

Worldwide, chronic obstructive pulmonary disease (COPD) is the fourth cause of death. Exacerbations have a negative impact on the prognosis of COPD and the frequency and severity of these episodes are associated with a higher patient mortality. Exacerbations are the first cause of decompensation, hospital admission and death in COPD. The incidence of exacerbations has mainly been estimated in populations of patients with moderate-severe COPD requiring hospital care. However, little is known regarding the epidemiology of exacerbations in patients with less severe COPD forms. It is therefore possible that a high number of these less severe forms of exacerbations are underdiagnosed and may, in the long-term, have certain prognostic importance for the COPD evolution. The aim of this study was to know the incidence and risk factors associated with exacerbations in patients with COPD in primary care. A prospective, observational, 3-phase, multicentre study will be performed involving: baseline evaluation, follow up and final evaluation. A total of 685 smokers or ex-smokers from 40 to 80 years of age with COPD, without acute respiratory disease or any other long-term respiratory disease will be randomly selected among the population a...Continue Reading

References

Aug 2, 2001·Archivos de bronconeumología·J Alvarez-SalaUNKNOWN Sociedad Española de Medicina de Familia y Comunitaria (semFYC)
Oct 9, 2001·The European Respiratory Journal·P M MeekD Anderson
Jul 2, 2002·American Journal of Respiratory and Critical Care Medicine·UNKNOWN ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories
Jan 30, 2003·Thorax·J Garcia-AymerichUNKNOWN Estudi del Factors de Risc d'Agudització de la MPOC investigators
Mar 8, 2003·Archives of Internal Medicine·Jean BourbeauUNKNOWN Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du Québec
Mar 12, 2003·Chest·Marc MiravitllesRamon Gisbert
Jun 11, 2003·The European Respiratory Journal. Supplement·S Burge, J A Wedzicha
Feb 20, 2004·Respiratory Medicine·R PauwelsC G Löfdahl
Mar 3, 2004·American Journal of Respiratory and Critical Care Medicine·Tom M A WilkinsonJadwiga A Wedzicha
Jun 29, 2004·The European Respiratory Journal·B R CelliUNKNOWN ATS/ERS Task Force
Feb 5, 2005·Respirology : Official Journal of the Asian Pacific Society of Respirology·UNKNOWN Asia Pacific COPD Roundtable Group
Aug 19, 2006·Respirology : Official Journal of the Asian Pacific Society of Respirology·Giovanni ViegiLaura Carrozzi
Feb 13, 2008·International Journal of Clinical Practice·C LlorUNKNOWN EVOCA study group
May 29, 2008·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Rachel E JordanKar Keung Cheng

❮ Previous
Next ❯

Citations

May 19, 2010·Expert Review of Respiratory Medicine·Sally Spencer
Jun 10, 2020·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Anton E LaffinTessa Kate Huncke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.